Level One Final Reports

This phase of the strategic planning process involved discussions with the research community in a series of 23 Working Group meetings.  Each meeting resulted in a final report.

• Cardiovascular #1: Coronary Artery Disease and Atherosclerosis



• Cardiovascular #2: Heart Failure and Cardiomyopathy



• Cardiovascular #3: Arrhythmias



• Cardiovascular #4: Vascular Diseases and Hypertension



• Cardiovascular #5: Valvular and Congenital Heart Diseases



• Cardiovascular #6: Regenerative and Reparative Medicine



• Cardiovascular #7: Emerging and Evolving Technologies



• Cardiovascular #8: From Discovery to Clinical Application



• Cardiovascular #9: Translation, Implementation, and Community Research



• Cardiovascular #10: Personalized Medicine Planning



• Cardiovascular #11: Bioinformatics and Computational Biology



• Cardiovascular #12: Clinical Trials Methodology



• Lung #1: Development and Early Origins of Disease



• Lung #2: Integrative Approaches to Pathogenic Research



• Lung #3: Inflammation/Injury; Remodeling, Repair and Replacement



• Lung #4: Personalized Medicine



• Lung #5: Enabling Therapeutic Trials and Translational Research



• Lung #6: New Investigation Workshop



• Blood #1: Critical Role of Inflammation in Ischemic Disorders



• Blood #2: Diagnosis and Treatment of Thrombotic Disorders



• Blood #3: Cellular Therapeutics



• Blood #4: Global Blood Safety and Availability



• Blood #5: Acquired and Inherited Blood Diseases

The Institute also convened a planning conference, The Future of Cardiovascular Disease: Today's Decisions...Tomorrow's Outcomes, on September 20, 2006. Its purpose was to explore the development of a national knowledge network to narrow the gaps between research discovery and application.